Overview

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Status:
Not yet recruiting

Trial end date:
2028-02-01

Target enrollment:

Participant gender:

Summary

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative chemotherapy with FLOT regimen and trastuzumab in combination with toripalimab in participants with resectable HER2 positive locally advanced gastric or esophagogastric junction adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Yu jiren

Treatments:

Docetaxel
Leucovorin
Oxaliplatin
Trastuzumab